<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647112</url>
  </required_header>
  <id_info>
    <org_study_id>UC-EpiCheck-EU-01</org_study_id>
    <nct_id>NCT02647112</nct_id>
  </id_info>
  <brief_title>Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma</brief_title>
  <official_title>Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma A Multicenter, Prospective Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nucleix Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nucleix Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to determine the performance characteristics (sensitivity and specificity) of
      the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial to determine the performance characteristics (sensitivity and specificity) of
      the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology in patients
      under monitoring for reccurrence of bladder cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity (the proportion of positives that are correctly identified as such by the gold standard)</measure>
    <time_frame>Day 1</time_frame>
    <description>the proportion of positives that are correctly identified as such by the gold standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity (the proportion of negatives that are correctly identified as such by the gold standard)</measure>
    <time_frame>Day 1</time_frame>
    <description>the proportion of negatives that are correctly identified as such by the gold standard</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Bladder EpiCheck</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urine sample will be tested with the Bladder EpiCheck in conjunction with cystoscopy and cytology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Practice of medicine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Practice of medicine including cystoscopy and cytology</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bladder EpiCheck</intervention_name>
    <description>Urine test for the monitoring of bladder cancer recurrence</description>
    <arm_group_label>Bladder EpiCheck</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient diagnosed with incident or recurrent urothelial cell carcinoma and undergoing
             surveillance monitoring for urothelial cell carcinoma

          -  Has all urothelial cell carcinoma tumor resected within the past 12 months

          -  Has a plan for cystoscopic surveillance

        Exclusion Criteria:

          -  Planning to undergo radical cystectomy or chemotherapy-radiation for UCC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shmulik Adler</last_name>
    <role>Study Director</role>
    <affiliation>Nucleix Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fred Witjes, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shmulik Adler</last_name>
    <phone>972-8-9161616</phone>
    <email>shmulik@nucleix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tubingen University Medical Center</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oshrat Parpara</last_name>
      <email>oshratpa@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Ilan Leibovitch, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZGT Medical Center</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Van Valenberg</last_name>
      <phone>+31 (0)24 361 95 15</phone>
      <email>Hans.vanValenberg@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Fred Witjes, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall D'Hebron Medical Center</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Lozano, MD</last_name>
      <phone>636244960</phone>
      <phone_ext>6518</phone_ext>
      <email>flozano@vhebron.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder cancer</keyword>
  <keyword>Urine</keyword>
  <keyword>Methylation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

